Behind-the-counter statins: a silver bullet for reducing costs and increasing access?

Area of Science:

• Pharmacoeconomics
• Health Services Research
• Drug Utilization Studies

Background:

• The 2004 policy change in the United Kingdom allowed simvastatin, a widely prescribed statin, to be dispensed behind-the-counter (BTC).
• Understanding the impact of such regulatory shifts on medication access, cost, and patient outcomes is crucial for healthcare policy.

Purpose of the Study:

• To evaluate the effects of introducing behind-the-counter (BTC) simvastatin on its utilization, pricing, and associated expenditures.
• To analyze the economic and access implications of transitioning a prescription-only statin to a BTC status.

Main Methods:

• Utilized a difference-in-differences (DID) analysis comparing the UK's simvastatin market before and after the 2004 BTC policy change.
• Employed secondary data from 1997-2007 on simvastatin utilization, prices, and expenditures in the UK and four control countries where it remained prescription-only.
• Controlled for potential confounding factors by comparing trends in the UK against those in non-BTC countries.

Main Results:

• The introduction of behind-the-counter simvastatin in the UK resulted in a statistically significant increase in the drug's utilization.
• A concurrent significant decrease in total expenditures for simvastatin purchases was observed following the policy change.
• The observed effects on utilization and expenditures were robust across various model specifications.

Conclusions:

• Transitioning statins, such as simvastatin, to a behind-the-counter (BTC) availability model demonstrates potential for dual benefits.
• Such policy changes can simultaneously enhance patient access and increase medication use while reducing overall healthcare spending on these drugs.